Avacta halts sale of Covid-19 rapid antigen lateral flow test to boost Omicron sensitivity
Britain’s biotech firm Avacta Group on Monday (January 10) announced halting sales of its Covid-19 rapid antigen lateral flow test AffiDX to replace antibodies...